Metabolic abnormalities in HIV-infected patients: An update

被引：7
作者：
Brown T.T. [1 ]
Cofrancesco Jr. J. [1 ]
机构：
[1] Baltimore, MD 21287
来源：
Current Infectious Disease Reports | 2006年 / 8卷 / 6期
关键词：
Metformin; Rosiglitazone; Tenofovir; National Cholesterol Education Program; Abacavir;
D O I：
10.1007/s11908-006-0025-5
中图分类号：
学科分类号：
摘要：
In recent years, substantial progress has been made in our understanding of the pathogenesis, risk factors, and treatment of glucose and lipid abnormalities in HIV-infected patients. Newer antiretrovirals, such as abacavir and tenofovir in the nucleoside reverse transcriptase class and atazanavir in the protease inhibitor class, have been shown to improve metabolic profiles compared to other medications. In addition, new information regarding the efficacy of glucose and lipid-lowering medications in HIV-infected patients has become available. It has also been demonstrated that aggressive risk factor modification can reduce the burden of cardiovascular disease in this population. This article reviews these recent advances in order to help providers respond to these important clinical challenges. Copyright © 2006 by Current Science Inc.
引用
收藏
页码：497 / 504
页数：7
相关论文
共 68 条
[11]  
Moyle G., Sabin C., Cartledge J., Et al., A 48-week, randomized open-label comparative study of tenofovir DF vs abacavir as substitutes for a thymidine analog in persons with lipoatrophy and sustained virological suppression on HAART, 12th Conference on Retroviruses and Opportunistic Infections, (2005)
[12]  
Schewe C.K., Maserati R., Wassmer G., Et al., Improved lipid profiles and maintenance of virologic control in heavily pretreated HIV-infected patients who switched from stavudine to tenofovir treatment, Clin Infect Dis, 42, pp. 145-147, (2006)
[13]  
da Silva B., Albrecht M., Benson C., Et al., Improved metabolic profile with replacement of stavudine by tenofovir DF after 6 years of a lopinavir/ritonavir-based regimen, 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, (2005)
[14]  
Llibre J.M., Domingo P., Perez M.J., Et al., Improvements in dyslipidemia at 48 weeks following substitution of stavudine with tenofovir DF, 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, (2005)
[15]  
Van Der Lee M., Vogel M., Schippers E., Et al., Pharmacokinetics and pharmacodynamics of combined use of lopinavir /ritonavir and rosuvastatin in HIV-infected patients, 13th Conference on Retroviruses and Opportunistic Infections, (2006)
[16]  
Mallon P.W., Miller J., Kovacic J.C., Et al., Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men - A randomized, placebo-controlled study, AIDS, 20, pp. 1003-1010, (2006)
[17]  
Calza L., Manfredi R., Chiodo F., Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART, Infection, 30, pp. 26-31, (2002)
[18]  
Rao A., D'Amico S., Balasubramanyam A., Maldonado M., Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy, Am J Med Sci, 327, pp. 315-318, (2004)
[19]  
de Truchis P., Treatment of hypertriglyceridemia in HIV-infected patients under HAART by polyunsaturated acids: A double blind randomized prospective trial in 122 patients, 12th Conference of Retroviruses and Opportunistic Infections, (2005)
[20]  
Wohl D.A., Tien H.C., Busby M., Et al., Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertri-glyceridemia, Clin Infect Dis, 41, pp. 1498-1504, (2005)
1234567